YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline De…
Gainers Staar Surgical (NASDAQ:STAA) shares rose 15.3% to $33.9 during Wednesday's after-market session. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. Precision Optics Corp (NASDAQ:P…
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceuti…
Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly. Claim 30% Off TipRanks Unlock hedge…
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Health care stocks climbed Friday afternoon, with the NYSE Health Care Index rising 1.7% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, t…
Psyence Biomedical Ltd. Expansion supports accelerated enrollment and advancement of the Company’s lead clinical asset NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”),…
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, to…
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, to…
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued a…
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.…
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of it…
Psyence Biomedical (PBM [https://seekingalpha.com/symbol/PBM]) has announced the effective date of its 1-for-6.25 reverse stock split of the company's issued and outstanding common shares. The common shares are expected to begin trading on…
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued a…
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, to…
DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning’s market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term visi…
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, to…
Key Takeaways; Cannabis Sector Village Farms Broke New Ground with Vape Launch in Quebec Organigram Announced Former BAT Strategy Chief as New CEO MTL Cannabis Posted Solid Second Quarter Results with Strong Margins and Improved Balance Sh…
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, to…
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmi…
Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:PBM [https://www.ch…
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT COMM [https://www.chartmill.com/stoc…
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/pro…
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psyche…
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT PBM…
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT PHLT [https://www.chartmill.com/stock/quote/PHLT/profile] 114.0% In an impressive move…
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT PHLT [https:…
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT VRME [h…
Investing.com -- Psyence Biomedical Ltd. (NASDAQ:PBM) stock surged 70% after the company announced that its strategic partner, PsyLabs, successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all mi…
NEW YORK - Psyence Biomedical Ltd. (NASDAQ:PBM), a micro-cap biotech company with a market capitalization of $3.15 million, announced Thursday that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkalo…
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds…
NEW YORK - Psyence Biomedical Ltd. (NASDAQ: PBM), currently trading at $4.37 with a market capitalization of $2.55 million, has regained compliance with all Nasdaq continued listing requirements following a hearing on May 29, the company a…
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the ba…
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that…